Combination productSupplement
Bacillus subtilis clinical trials
- studies test it
- 11
- open now
- 2
- in phase 3
- 0
- first study started
- 2013
Keep track of what changes. Save the Bacillus subtilis studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 6
National Children's Hospital, Vietnam (3) · Anabio R&D (2) · DreamTec Research Limited (2) · University of Edinburgh (1) · University of Florida (1) · Bioagile Therapeutics Pvt. Ltd. (1) · The Third Xiangya Hospital of Central South University (1)
Often tested with
Tested in the same studies.
Bacillus clausii (5) · Acetylcysteine (1) · Cefotaxime (1) · Ciprofloxacin (1) · Lactobacillus plantarum (1) · Bifidobacterium animalis (1)
Studies
Open first, then newest update. How each study uses Bacillus subtilis is read from its arms, and is right about nine times in ten.
Testing it · 11
- To Evaluate the Effect of Bacillus Subtilis Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults.Enrolling by invitationNot applicableBioagile Therapeutics Pvt. Ltd.NCT07377942Written as Probiotics (Bacillus Subtilis)
- Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's DiseaseRecruitingNot applicableThe Third Xiangya Hospital of Central South UniversityNCT07123207Written as Bacillus subtilis Capsules
- Bacillus Subtilis in Parkinson's DiseaseCompletedNot applicableUniversity of EdinburghNCT06487975Written as Bacillus Subtilis
- Efficacy of Probiotics (LiveSpo Navax) in Preventing Respiratory Diseases in ChildrenCompletedNot applicableAnabio R&DNCT06148194Written as Probiotic 1
- Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infectionsActive, not recruitingNot applicableNational Children's Hospital, VietnamNCT05929599Written as LiveSpo Navax
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis MediaCompletedNot applicableAnabio R&DNCT05804123Written as LiveSpo Navax®
- The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis SporesCompletedNot applicableDreamTec Research LimitedNCT05057923Written as Bacillus subtilis
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in ChildrenCompletedNot applicableNational Children's Hospital, VietnamNCT05378022Written as LiveSpo Navax
- COVID19 Oral Vaccine Consisting of Bacillus Subtilis SporesCompletedNot applicableDreamTec Research LimitedNCT05239923Written as Bacillus subtilis
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in ChildrenCompletedNot applicableNational Children's Hospital, VietnamNCT05164692Written as LiveSpo Navax
- The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and InflammationCompletedPhase 1University of FloridaNCT01879098Written as Probiotic: Bacillus subtilis
Codes
What other systems call Bacillus subtilis · ClinicalTrials.gg INT015639
- UNII (FDA) 8CF93KW41WBACILLUS SUBTILISConfirmed FDA, Wikidata
- RxNorm 1311119One source FDA
- Wikidata Q131238Bacillus subtilisConfirmed FDA, Wikidata
- NCI Thesaurus C86167Bacillus subtilisOne source FDA
- DrugBank DB11347One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8CF93KW41W | BACILLUS SUBTILIS | Confirmed FDA, Wikidata |
| RxNorm | 1311119 | — | One source FDA |
| Wikidata | Q131238 | Bacillus subtilis | Confirmed FDA, Wikidata |
| NCI Thesaurus | C86167 | Bacillus subtilis | One source FDA |
| DrugBank | DB11347 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.